Brief: Sanofi Spokesperson Says Nuvaxovid to Be Available Across U.S. for 2026-27 Respiratory Virus Season
BRIEF-Sanofi Spokesperson Says Nuvaxovid to Be Available Across U.S. for 2026-27 Respiratory Virus Season Aug 28 (Reuters) - Sanofi Spokesperson:
NUVAXOVID WILL BE AVAILABLE ACROSS U.S. FOR THE 2026-2027 RESPIRATORY VIRUS SEASON- SANOFI SPOKESPERSON
WELCOME APPROVAL OF UPDATED FORMULATION OF NUVAXOVID FOR USE DURING 2026-2027 RESPIRATORY VIRUS SEASON - SANOFI SPOKESPERSON
Source text: [ID:]
Further company coverage: SASY.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sanofi SA
See all newsEdenTree fund manager Hiorns has bought up French stocks despite civil unrest (updated)
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Brief: Sanofi Starts Work On Insulin Facility In Germany
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Europe Research Roundup: AJ Bell, CMC Markets, Nestle